Related Experiment Video
Updated: Feb 28, 2026

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
Published on: August 22, 2025
The Use of Cannabinoids in Treating Dementia
Megan Weier1,2, Wayne Hall3,4
1National Drug and Alcohol Research Centre, The University of New South Wales, Sydney, Australia.
Purpose Of Review:
To review and summarise the current evidence on the safety and efficacy of using cannabinoids to treat behavioural and neuropsychiatric symptoms of dementia.
Recent Findings:
Two randomised controlled trials testing a synthetic form of tetrahydrocannabinol have shown that while well tolerated, there was no significant therapeutic effect, based on changes to scores on the neuropsychiatric inventory (NPI). Case reports and open label trials have indicated that there may be some therapeutic benefit of adding synthetic cannabinoids as an adjunctive therapy to reduce agitation, aberrant motor behaviour and nighttime behaviour. More well-controlled clinical trials in older populations with varying severity of dementia are needed to evaluate the effectiveness of cannabinoids in treating behaviour symptoms of dementia. We provide suggestions for designing such trials and evaluating possible adverse effects of cannabinoids on cognitive and neuropsychiatric functioning.
Related Concept Videos
Alzheimer's Disease: Treatment
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Dementia
The progression of dementia is generally gradual....
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

